Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Allen S. Lichter, MD, of the Value in Cancer Care Consortium, interviews Clifford A. Hudis, MD, Chief Executive Officer of ASCO, on the question of whether cancer drug prices in the United States are the problem, or just the symptom, of a larger systemic issue.

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Oct

Today In Oncology

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Varsha Gandhi, PhD, on Ibrutinib

Opportunities to Optimize Cancer Policies Panel Discussion

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Thymic Health Associated With ICI Response

First-Line PD-1/PD-L1 Inhibitors vs BRAF Plus MEK Inhibitors in BRAF V600E-Mutated Metastatic NSCLC

Multidisciplinary Program Doubles Lung Cancer Screening Rates

New Leadership Elected to the American Society of Hematology

Lisaftoclax Regimens Effective in Plasma Cell Disorders